The life science and biotech PR distribution service

New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021

 Accelerate Diagnostics Logo

  • In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality
  • Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations

TUCSON, Ariz., June 30, 2021 / B3C newswire / -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.

The ePoster presentations are from real-world clinical use of the Accelerate Pheno system in diverse health systems and include endpoints for microbiology test turnaround time, antimicrobial use, and a subgroup analysis that measured 30-day mortality. The data further highlight the clinical benefits of using the Accelerate Pheno system, with significant improvements in multiple endpoints, including a statistically significant reduction in 30-day mortality in the Accelerate Pheno arm (AXDX) versus standard of care testing arm (SOC) in a subset of patients on ineffective empirical antibiotic treatment (6.0% in AXDX vs. 15.9% in SOC).

The Company’s presentations, which are available now on the ECCMID 2021 website, include:

Antimicrobial Use in Patients with Bloodstream Infections from 4 Hospitals in the IOAS Study: A Quasi-Experimental Multicenter Study of the Accelerate PhenoTest® BC Kit
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 661
ePoster Session: S147-3c

Evaluating the Impact of the Accelerate PhenoTest® BC Kit (AXDX) on Patients with Bloodstream Infections Receiving Ineffective Empirical Antibiotic Treatment: IOAS Study Experience of 4 Hospitals
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 664
ePoster Session: S138-2b

Impact of the Accelerate PhenoTest® BC Kit on Time to Results for Pathogens from Bloodstream Infections: IOAS (Improving Outcomes and Antibiotic Stewardship) Study Experience of 4 Hospitals
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 758
ePoster Session: S147-3c

To view the presentations or more information, visit the ECCMID 2021 website at: https://www.eccmid.org/.


About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.


Forward-Looking Statements
Certain of the statements made in this press release are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such forward looking statements include any implication that the results of the new landmark study will be realized at other customers using the Accelerate Pheno system. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions, and regulatory approvals. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.



Accelerate Diagnostics
Laura Pierson
+1 520 365-3100
This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: Accelerate Diagnostics Inc.


Keywords: Humans; Antimicrobial Stewardship; Hematologic Tests; Anti-Bacterial Agents; Sepsis; Drug Resistance, Microbial; Anti-Infective Agents; Hospitals; Delivery of Health Care; Decision Making; United States; North America



Published by B3C newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.